Perspectives on the safety of a JAK inhibitor in RA, PsA, and AS–Sponsored by AbbVie Medical Affairs

Drs. Pendleton Wickersham (Arthritis Associates PA, San Antonio, TX), Kevin Winthrop (OHSU, Portland, OR), and Christopher Ritchlin (URMC, Rochester, NY) come together to share their experiences discussing with patients the benefit-risk of a JAK inhibitor.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Subscribe and Rate

Subscribe to the RheumNow podcast on your favorite podcast app to get automatic downloads of the latest content. Listen in the car, airplane, anywhere! We also reach more listeners through reviews from our users. Consider leaving a review!
 

 

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.